Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity.
Saved in:
| Title: | Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity. |
|---|---|
| Authors: | Flaherty SE 3rd; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Bezy O; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Zheng W; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Yan D; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Li X; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Jagarlapudi S; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Albuquerque B; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Esquejo RM; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Peloquin M; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Semache M; Domain Therapeutics North America, Montréal, QC, Canada., Mancini A; Domain Therapeutics North America, Montréal, QC, Canada., Kang L; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Drujan D; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Breitkopf SB; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Griffin JD; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Jean Beltran PM; Machine Learning and Computational Sciences, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Xue L; Machine Learning and Computational Sciences, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Stansfield J; Biostatistics, Early Clinical Development, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Pashos E; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Shakey Q; Biomedicine design, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Pehmøller C; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Monetti M; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Birnbaum MJ; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Fortin JP; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Wu Z; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA. Zhidan.wu@pfizer.com. |
| Source: | Nature communications [Nat Commun] 2023 Jul 04; Vol. 14 (1), pp. 3953. Date of Electronic Publication: 2023 Jul 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
